Studies Show Crescendo Bioscience’s Vectra(TM) DA Can Track Early Response to Rheumatoid Arthritis Therapy and Predict Joint Damage at the Molecular Level
Published: May 25, 2011
Crescendo Bioscience™ today announced data indicating that Vectra™ DA, a first-in-class multi-biomarker blood test used to assess rheumatoid arthritis (RA) disease activity, provides physicians with an objective measure which may help determine whether patients are responding to therapy. Additional studies show that the score from the Vectra DA algorithm has the potential to predict progressive joint damage and is robust in RA patients who have common comorbid conditions. Two additional studies confirmed Vectra DA algorithm’s ability to quantify RA disease activity including the ability to discriminate between low disease activity and remission. These data were presented at the European League Against Rheumatism’s (EULAR) Annual European Congress of Rheumatology in London, May 25 – 28, 2011. Additional studies of pipeline products were also presented, including work to develop a multi-biomarker test for risk of structural damage in RA.